CTRI/2019/10/021737已完成未知
Safety of terlipressin in patients with acute on chronic liver failure-an observational study. - TerliACLF
o sponsor required0 个研究点目标入组 116 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 116
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Acute on chronic liver patients (as per APASL criteria) aged between 18-75years who are receiving terlipressin injection will be included. Baseline clinical, demographic and biochemical data will be recorded.
排除标准
- •Refusal to participate
研究者
相似试验
招募中
3 期
Effect of Terlipressin Drug in Patients with Liver Cancers undergoing surgeryCTRI/2021/11/038076Tata Memorial Hospital
已完成
不适用
Terlipressin infusion in Living Donor Liver TransplantatioPACTR201402000752252ational Liver Institute, Menoufiya University50
尚未招募
2 期
Comparison of Terlipressin and low dose Terlipressin and noradrenalin in HRS-AKI patients of ACLFCTRI/2023/10/058546on sponsered
已完成
不适用
Terlipressin versus albumin in the prevention of paracentesis-associated adverse events in patients with cirrhosis and tense ascitesCirrhosis of the liver/ascitesDigestive SystemFibrosis and cirrhosis of liverISRCTN36383299Foundation for Liver and Gastrointestinal Research (SLO) (Netherlands)84
已完成
3 期
The impact of continuous terlipressin infusion on complications of end-stage liver diseaseSarcopaeniaInflammationMalnutritionAscitesInfectionImmune functionOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonMusculoskeletal - Other muscular and skeletal disordersDiet and Nutrition - Other diet and nutrition disordersInflammatory and Immune System - Other inflammatory or immune system disordersCirrhosisHepatic encephalopathyACTRN12619000891123Austin Health30